News | August 02, 2011

Accuray Symposium at Joint AAPM/COMP Meeting Highlights Quality Assurance in Radiation Oncology

Aug. 2, 2011 — Accuray Inc. announced it will showcase the CyberKnife robotic radiosurgery system and the TomoTherapy radiation therapy treatment system at the 2011 Joint American Association of Physicists in Medicine (AAPM)/Canadian Organization of Medical Physicists (COMP) meeting. The company will also host a joint symposium examining best practices for quality assurance (QA) in radiation oncology. The 2011 Joint AAPM/COMP meeting takes place July 31-Aug. 4, 2011 in Vancouver, British Columbia.

Accuray will host a symposium at the Fairmont Pacific Rim Star Sapphire Ballroom entitled "Best Quality Assurance Programs for Today's Radiation Oncology Platforms." Sonja Dieterich, Ph.D., DABR, chief of clinical physics at Stanford University School of Medicine, will discuss the protocols and recommendations of task group TG-135, which has been dedicated to setting QA standards in the field of robotic radiosurgery.

Sasa Mutic, Ph.D., DABR, chief of clinical medical physics and associate professor of radiation oncology at Washington University School of Medicine, will discuss how systems' engineering principles can be applied to radiotherapy QA and quality compliance (QC). Attendees interested in participating in the symposium may register online.

In addition to the symposium, several studies from leading hospitals and academic centers will showcase both the CyberKnife system and the TomoTherapy system. Highlights from the more than 60 CyberKnife and TomoTherapy-related topics from the conference include:

-"Experience with Helical TomoTherapy Commissioning and Quality Assurance of Twin Peaks Linac vs. Earlier Models"—Conducted at the Pomona Valley Hospital Medical Center in Pomona, Calif., this study evaluated the new Twin Peak linear accelerator in the TomoTherapy system. Researchers found beam performance to be consistent with that of a treatment unit employing an earlier model of linear accelerator. Additionally, this study found that throughout nine months of clinical use, no changes in beam characteristics were observed. The study concludes that the new linear accelerator represents an improvement in technology in terms of beam stability and in the lifetime of this system component.

-"CyberKnife Treatment of Endometrial Cervical Cancer"—Conducted at the Fox Chase Cancer Center in Philadelphia, Pa., this research investigated the potential use of the CyberKnife system for the treatment of cervical cancer as an alternative to brachytherapy, an invasive and often painful treatment option. As the authors state, this study demonstrated that CyberKnife treatment can be a viable alternative to endometrial brachytherapy treatments, which may greatly improve the patient care.

-"CyberKnife Treatment for Early Stage Oral Tongue Cancer – Feasibility Study"—Conducted at the Fox Chase Cancer Center in Philadelphia, Pa., this study evaluated use of the CyberKnife system to treat oral tongue cancer. The treatment planning study found that the system could deliver conformal dose in 5 fractions that kept radiation dose to the mandible low, providing patients with a more comfortable and less invasive alternative to conventional brachytherapy. Authors estimate treatment time will be 18 min./fraction.

For more information: www.accuray.com

Related Content

RayStation Selected for New Carbon Ion Therapy Center in Japan
News | Treatment Planning | January 18, 2018
January 18, 2018 – RayStation has been chosen as the treatment planning system for a new carbon-ion therapy facility
Raysearch Receives First Order for the Raycare Oncology Information System
News | Oncology Information Management Systems (OIMS) | January 18, 2018
January 18, 2018 – Anderson Regional Cancer Center (ARCC) in Meridian, Mississippi, has placed the first order for...
Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
FDA Clears GammaPod Stereotactic Radiotherapy System for Breast Cancer Treatment
Technology | Stereotactic Body Radiation Therapy (SBRT) | December 22, 2017
The U.S. Food and Drug Administration (FDA) has cleared the new GammaPod noninvasive stereotactic radiotherapy system...
Overlay Init